News
IT company launches new cycle-based fitness app
The app aims to empower women by helping them better understand their bodies and achieve their goals
The IT company Amo has launched a “cycle-based” app to help women incorporate physical activity into their lives.
HARNA is a cycle-based fitness app that aims to maximise the effectiveness of workouts by taking into account the different phases of the menstrual cycle.
The app claims to empower women by helping them better understand their bodies and achieve their goals, including syncing physical activity with the menstrual cycle, overcoming common obstacles such as lack of energy and menstrual pain and enhancing the joy in sports.
“Women’s bodies and health are complex, and many women build their life around their menstrual cycle,” says Artur Markarian, CEO of HARNA.
“Modern society finally started understanding and respecting it. However, 57 per cent of women still lack knowledge of their bodies.
“Furthermore, around 42 per cent of women believe that their menstrual cycle harms exercise training and performance.
“We simply want to destroy the myth that women can’t exercise during menstruation and educate them how to do it in a way that does not cause any harm to their health and body but helps to cease pain during their period and improve their results.”
HARNA argues that most fitness apps are not adjusted to the complexity of the female body, menstrual cycle, lifestyle, and habits.
The company conducted numerous interviews with women and found that 65 per cent of them refrain from exercising during the first two days of their menstrual cycle, with 90 per cent expressing willingness to perform exercises that would cease pain symptoms during periods.
“Women deserve to know the capabilities and advantages of their body, and HARNA will help them to discover it,” says Markarian.
The company says it worked closely with medical experts and sports coaches to develop the app which provides personalised fitness plans and classes such as HIIT, cardio, pilates and yoga.
The team has plans to expand its offerings by introducing specialised programmes for women going through pregnancy, postpartum recovery and menopause.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Wellness2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






